Becker Marc, Graf Claudine, Tonak Marcus, Radsak Markus P, Bopp Tobias, Bals Robert, Bohle Rainer M, Theobald Matthias, Rommens Pol-Maria, Proschek Dirk, Wehler Thomas C
Institute of Pathology, Saarland University Medical Center, Homburg, Saarland D-66421, Germany; Interdisciplinary Sarcoma Working Group, Center of Orthopaedic and Trauma Surgery, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Rhineland-Palatinate D-5513, Germany.
III Department of Internal Medicine, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Rhineland-Palatinate D-55131, Germany.
Oncol Lett. 2016 Aug;12(2):1257-1264. doi: 10.3892/ol.2016.4784. Epub 2016 Jun 24.
Undifferentiated pleomorphic sarcoma not otherwise specified belongs to the heterogeneous group of soft tissue tumors. It is preferentially located in the upper and lower extremities of the body, and surgical resection remains the only curative treatment. Preclinical animal models are crucial to improve the development of novel chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma. However, this approach has been hampered by the lack of reproducible animal models. The present study established two xenograft animal models generated from stable non-clonal cell cultures, and investigated the difference in chemotherapeutic effects on tumor growth between undifferentiated pleomorphic sarcoma and . The cell cultures were generated from freshly isolated tumor tissues of two patients with undifferentiated pleomorphic sarcoma. For the analysis, these cells were injected subcutaneously into immunodeficient mice. The mice were monitored for tumor appearance and treated with the most common or innovative chemotherapeutic agents available to date. Furthermore, the same drugs were administered to cell cultures. The most effective tumor growth inhibition was observed with doxorubicin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as vorinostat. In the xenograft mouse model, the combination of doxorubicin and the tyrosine kinase inhibitor pazopanib induced a significant tumor reduction. By contrast, treatment with vorinostat did not reduce the tumor growth. Taken together, the results obtained from drug testing differed significantly from the results. Therefore, the novel and reproducible xenograft animal model established in the present study demonstrated that models are required to test potential chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma prior to clinical use, since animal models are more similar to humans, compared with cell cultures.
未另行规定的未分化多形性肉瘤属于软组织肿瘤的异质性组。它优先位于身体的上肢和下肢,手术切除仍然是唯一的治愈性治疗方法。临床前动物模型对于开发用于治疗未分化多形性肉瘤的新型化疗药物至关重要。然而,这种方法因缺乏可重复的动物模型而受到阻碍。本研究建立了两种由稳定的非克隆细胞培养物产生的异种移植动物模型,并研究了未分化多形性肉瘤与……之间对肿瘤生长的化疗效果差异。细胞培养物来自两名未分化多形性肉瘤患者新鲜分离的肿瘤组织。为了进行分析,将这些细胞皮下注射到免疫缺陷小鼠体内。监测小鼠的肿瘤出现情况,并用迄今为止可用的最常见或创新的化疗药物进行治疗。此外,将相同的药物施用于……细胞培养物。观察到阿霉素和组蛋白脱乙酰酶抑制剂辛二酰苯胺异羟肟酸(SAHA,也称为伏立诺他)对肿瘤生长的抑制作用最为有效。在……异种移植小鼠模型中,阿霉素和酪氨酸激酶抑制剂帕唑帕尼的联合使用导致肿瘤显著缩小。相比之下,伏立诺他治疗并未降低肿瘤生长。综上所述,药物测试获得的结果与……结果有显著差异。因此,本研究建立的新型且可重复的异种移植动物模型表明,在临床使用前,需要……模型来测试用于治疗未分化多形性肉瘤的潜在化疗药物,因为与……细胞培养物相比,动物模型与人类更相似。